AstraZeneca Pharma India to launch Enhertu in January 2024
Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer
Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer
Additionally, Rs. 12.85 crores shall be infused into the P H Diagnostic by way of either Equity or Loan to pay the existing debt
Five batches across four programs of Biocon Academy participated in the graduation ceremony
His most recent stint was with Danone India as its Managing Director
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg are indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus
Lacosamide is indicated to treat partial-onset seizures
10+ emerging markets, Japan & ANZ transition in final phase
Receives registration of Valganciclovir powder for oral solution in Germany
Subscribe To Our Newsletter & Stay Updated